Therapeutic Crossroads of Diabetes-Related Skin Disorders: Unveiling Mechanistic Pathways and the Ethnobotanical Promise of Bioactive Remedies

Abstract

Introduction: Cutaneous consequences of diabetes mellitus, ranging from acanthosis nigricans to necrobiosis lipoidica, serve as key indications of systemic metabolic and immunological dysregulation. Complex converging mechanisms, such as oxidative endothelium damage, T-cell dysfunction, and hyperinsulinemia-induced IGF-1 receptor activation, are responsible for these manifestations. The objective of this review is to assess the therapeutic potential of particular ethnobotanical bioactives in reducing these processes and to clarify the molecular pathophysiology of these ailments

Objectives: The study elucidates the molecular interplay behind diabetic dermatopathies and critically analyzes the therapeutic efficacy of ethnobotanical bioactives in bridging the gap between ancestral medical knowledge and modern precision treatments.

Methods: To consolidate information linking diabetic dermatopathology and phytopharmacology, we did a comprehensive assessment of the literature across major biological databases (PubMed, Scopus, and Web of Science). The study focused on the bioactive profiles of Trigonella foenum-graecum, Glycyrrhiza glabra, Mahonia aquifolium, and Centella asiatica, specifically looking at their molecular interactions with inflammatory and metabolic signaling cascades.

Results: The investigation revealed that several key phytochemicals, such as certain flavonoids, saponins, and terpenoids, have powerful biological actions that directly counteract diabetic skin disease. These agents enhanced insulin sensitivity and reduced cytokine storms by inhibiting JAK-STAT and NF-κB signaling pathways. Furthermore, these bioactives stimulated skin regeneration and reduced oxidative stress, addressing the underlying causes of endothelial dysfunction in diabetic dermopathy.

Conclusions: Ethnobotanical agents represent a scientifically validated, multi-targeted therapeutic strategy for managing diabetic cutaneous complications.By combining ancestral pharmacological knowledge with modern molecular insights, these bioactive medicines provide a fresh, integrated approach to dermatologic treatment, justifying their transition from traditional use to evidence-based clinical application in the diabetic community.